Sign up to save your podcasts
Or
Share Eligibility for Anti-Amyloid Treatment
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eligibility for Anti-Amyloid Treatment
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
View all episodes
By American Academy of Neurology
4.7
285285 ratings
Dr. Gregg Day talks with Dr. Vijay Ramanan about the clinical trial eligibility criteria for lecanemab treatment for participants with early Alzheimer disease and the generalizability of anti-amyloid treatment.
Read the related article in Neurology.
Visit NPub.org/Podcast for associated article links.
More shows like Neurology® Podcast
View all
NEJM This Week
321 Listeners
JAMA Clinical Reviews
504 Listeners
Practical Neurology Podcast
53 Listeners
The Curbsiders Internal Medicine Podcast
3,374 Listeners
JAMA Neurology Author Interviews
16 Listeners
Core IM | Internal Medicine Podcast
1,150 Listeners
Neurology Today in 5
24 Listeners
Annals On Call Podcast
194 Listeners
The Clinical Problem Solvers
518 Listeners
Neurology Minute
134 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
367 Listeners
Neurology Exam Prep Podcast
189 Listeners
The Curious Clinicians
375 Listeners
Ninja Nerd
325 Listeners
Continuum Audio
80 Listeners